Zum Inhalt springen
Home » Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). The post Biogen Completes Acquisition of Human Immunology Biosciences appeared first on Bio Tech Winners.

Biogen Completes Acquisition of Human Immunology Biosciences